Search
Close this search box.
Logo Asphalion

Generics Facilities, Sites, and Organizations self-identification 2018

FDA reporting period for self-identification opens May 1st to June 1st of 2017

FDA reporting period for self-identification opens May 1st to June 1st of 2017
May 2, 2017

Under GDUFA, human generic drug facilities, sites, and organisations are required to submit identification information electronically to FDA annually. The reporting period for the fiscal year 2018 is between May 1st and June 1st of 2017. 

Structured Product Labeling (SPL) is the standard that FDA intends to use for the exchange of drug establishment registration and drug listing information.  The SPL file should be created following the FDA technical specifications and it should be submitted to FDA through the Electronic Submissions Gateway (ESG).

Please refer to Guidance for Industry: Self-Identification of Generic Drug Facilities, Sites, and Organizations, that explains who is required to self-identify, what information is required for submission, and what the process is for submitting self-identification information. 

ASPHALION has extensive experience in SPL generation and electronic submission. If you need any support to comply with the self-identification requirement, please contact us: info@asphalion.com 

Search News & Events

  • Filter by category

Share

Related news and events

Christmas season greatings

Season’s Greetings

We wish you Happy ‘Xmas, Prosperous New Year and Health for you and your loved ones.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting